Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
130 participants
INTERVENTIONAL
2013-12-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Uric acid ≥7 mg/dL
This arm will receive allopurinol treatment. 50 subjects will be recruited.
allopurinol 300 mg./day
Uric acid ≥6 and <7
This arm will not receive allopurinol. 50 subjects will be recruited.
No intervention
Normouricemic
This arm is healthy controls. 30 subjects will be recruited.
Normouricemic
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
allopurinol 300 mg./day
No intervention
Normouricemic
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum uric acid level ≥7mg/dL
* Glomerular filtration rate ≥60 ml/min
Exclusion Criteria
* history of gout
* history of allopurinol use
* body mass index ≥35 kg/m2
* proteinuria ≥ 1gr/ day
* presence of autoimmune disease
* rheumatology associated disease
* presence of hypothyroidism or hyperthyroidism
* presence of diseases which may cause chronic inflammation or microalbuminuria (e.g. malignancy, chronic liver disease, hypertension, chronic lung disease)
30 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Medeniyet University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mehmet Kanbay
Associate Professor Doctor Mehmet Kanbay
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ali Bakan
Role: PRINCIPAL_INVESTIGATOR
Istanbul Medeniyet University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul Medeniyet University Goztepe Training and Research Hospital
Istanbul, Marmara, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mehmet Kanbay, Associate Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Allo2013
Identifier Type: -
Identifier Source: org_study_id